Immatics Nv (IMTX)

$12.13

+1.1

(+9.97%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Immatics Nv

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 5.92M → 30.44M (in $), with an average increase of 55.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -26.48M → -3.07M (in $), with an average increase of 376.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 53.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 234.1%

Performance

  • $10.99
    $12.24
    $12.13
    downward going graph

    9.4%

    Downside

    Day's Volatility :10.21%

    Upside

    0.9%

    downward going graph
  • $7.15
    $13.16
    $12.13
    downward going graph

    41.06%

    Downside

    52 Weeks Volatility :45.67%

    Upside

    7.83%

    downward going graph

Returns

PeriodImmatics NvSector (Health Care)Index (Russel 2000)
3 Months
-3.04%
-1.0%
0.0%
6 Months
31.99%
9.6%
0.0%
1 Year
18.0%
11.0%
0.0%
3 Years
1.0%
18.5%
-22.6%

Highlights

Market Capitalization
1.1B
Book Value
$2.66
Earnings Per Share (EPS)
-1.06
Wall Street Target Price
19.1
Profit Margin
-179.63%
Operating Margin TTM
-174.07%
Return On Assets TTM
-13.86%
Return On Equity TTM
-44.26%
Revenue TTM
54.0M
Revenue Per Share TTM
0.67
Quarterly Revenue Growth YOY
-57.699999999999996%
Gross Profit TTM
172.8M
EBITDA
-98.4M
Diluted Eps TTM
-1.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.19
EPS Estimate Next Year
-1.46
EPS Estimate Current Quarter
-0.22
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Immatics Nv(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 57.46%

Current $12.13
Target $19.10

Company Financials

FY18Y/Y Change
Revenue
4.3M
-
Net Income
-36.0M
-
Net Profit Margin
-834.06%
-
FY19Y/Y Change
Revenue
20.7M
↑ 389.36%
Net Income
-35.6M
↑ 0.94%
Net Profit Margin
-172.05%
↑ 662.01%
FY20Y/Y Change
Revenue
38.4M
↑ 69.4%
Net Income
-282.1M
↑ 622.56%
Net Profit Margin
-733.84%
↓ 561.79%
FY21Y/Y Change
Revenue
39.4M
↑ 11.23%
Net Income
-107.7M
↓ 58.55%
Net Profit Margin
-273.45%
↑ 460.39%
FY22Y/Y Change
Revenue
185.1M
↑ 397.17%
Net Income
40.2M
↓ 139.46%
Net Profit Margin
21.71%
↑ 295.16%
FY23Y/Y Change
Revenue
54.0M
↓ 68.76%
Net Income
-97.0M
↓ 358.55%
Net Profit Margin
-179.63%
↓ 201.34%
Q4 FY22Q/Q Change
Revenue
40.3M
↑ 149.99%
Net Income
-14.2M
↓ 36.65%
Net Profit Margin
-35.23%
↑ 103.78%
Q1 FY23Q/Q Change
Revenue
10.7M
↓ 73.98%
Net Income
-16.5M
↑ 14.03%
Net Profit Margin
-154.38%
↓ 119.15%
Q2 FY23Q/Q Change
Revenue
24.4M
↑ 128.2%
Net Income
-26.9M
↑ 62.73%
Net Profit Margin
-110.09%
↑ 44.29%
Q3 FY23Q/Q Change
Revenue
5.9M
↓ 73.49%
Net Income
-26.5M
↑ 7.64%
Net Profit Margin
-447.0%
↓ 336.91%
Q4 FY23Q/Q Change
Revenue
15.9M
↑ 168.66%
Net Income
-26.1M
↓ 1.29%
Net Profit Margin
-164.24%
↑ 282.76%
Q1 FY24Q/Q Change
Revenue
32.9M
↑ 91.24%
Net Income
-3.3M
↓ 88.25%
Net Profit Margin
-10.09%
↑ 154.15%
FY18Y/Y Change
Total Assets
166.8M
-
Total Liabilities
5.4M
-
FY19Y/Y Change
Total Assets
150.4M
↓ 7.92%
Total Liabilities
196.2M
↑ 3644.21%
FY20Y/Y Change
Total Assets
313.2M
↑ 89.64%
Total Liabilities
185.0M
↓ 14.12%
FY21Y/Y Change
Total Assets
197.8M
↓ 31.42%
Total Liabilities
170.5M
↑ 0.13%
FY22Y/Y Change
Total Assets
436.9M
↑ 133.51%
Total Liabilities
208.5M
↑ 29.27%
FY23Y/Y Change
Total Assets
510.0M
↑ 25.05%
Total Liabilities
284.9M
↑ 46.35%
Q4 FY22Q/Q Change
Total Assets
436.9M
↑ 15.11%
Total Liabilities
208.5M
↓ 19.31%
Q1 FY23Q/Q Change
Total Assets
412.7M
↓ 7.19%
Total Liabilities
194.6M
↓ 8.35%
Q2 FY23Q/Q Change
Total Assets
447.6M
↑ 8.38%
Total Liabilities
209.5M
↑ 7.61%
Q3 FY23Q/Q Change
Total Assets
437.5M
↑ 6.65%
Total Liabilities
189.7M
↓ 1.19%
Q4 FY23Q/Q Change
Total Assets
510.0M
↑ 16.58%
Total Liabilities
284.9M
↑ 50.18%
Q1 FY24Q/Q Change
Total Assets
705.8M
↑ 28.19%
Total Liabilities
272.7M
↓ 11.34%
FY18Y/Y Change
Operating Cash Flow
23.7M
-
Investing Cash Flow
-15.5M
-
Financing Cash Flow
27.1M
-
FY19Y/Y Change
Operating Cash Flow
79.5M
↑ 243.1%
Investing Cash Flow
-5.7M
↓ 62.56%
Financing Cash Flow
-2.1M
↓ 107.87%
FY20Y/Y Change
Operating Cash Flow
-105.3M
↓ 220.63%
Investing Cash Flow
-19.6M
↑ 215.26%
Financing Cash Flow
255.7M
↓ 11264.5%
FY21Y/Y Change
Operating Cash Flow
-92.6M
↓ 4.47%
Investing Cash Flow
8.5M
↓ 146.98%
Financing Cash Flow
-3.0M
↓ 101.26%
FY22Y/Y Change
Operating Cash Flow
107.3M
↓ 222.43%
Investing Cash Flow
-224.7M
↓ 2899.83%
Financing Cash Flow
132.5M
↓ 4834.4%
Q4 FY22Q/Q Change
Operating Cash Flow
-33.7M
↓ 2.16%
Investing Cash Flow
-96.6M
↑ 26.94%
Financing Cash Flow
113.0M
↑ 3395.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-25.9M
↓ 24.59%
Investing Cash Flow
-4.1M
↓ 95.88%
Financing Cash Flow
-944.4K
↓ 100.82%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.2M
↓ 72.14%
Investing Cash Flow
-18.4M
↑ 352.7%
Financing Cash Flow
39.8M
↓ 4309.12%

Technicals Summary

Sell

Neutral

Buy

Immatics Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immatics Nv
Immatics Nv
12.94%
31.99%
18.0%
1.0%
-19.4%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immatics Nv
Immatics Nv
15.24
NA
NA
-1.19
-0.44
-0.14
NA
2.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immatics Nv
Immatics Nv
Buy
$1.1B
-19.4%
15.24
-179.63%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    9.70%

  • Baker Bros Advisors LP

    6.25%

  • Wellington Management Company LLP

    6.16%

  • T. Rowe Price Investment Management,Inc.

    6.12%

  • Perceptive Advisors LLC

    4.45%

  • T. Rowe Price Associates, Inc.

    3.13%

Company Information

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l

Organization
Immatics Nv
Employees
432
CEO
Dr. Harpreet Singh Ph.D.
Industry
Health Technology

Discover More

FAQs